Description
Latin name
Mexidolum
Release form
Solution for i / o and i / m administration is colorless or slightly yellowish, transparent.
Packaging
5 ml – glass ampoules (5) – blister packs (1) – packs of cardboard.
Pharmacological action
Mexidol ® has antihypoxic, membrane-protective, nootropic, anticonvulsant, anxiolytic effects, increases the body’s resistance to stress. The drug increases the body’s resistance to the effects of the main damaging factors, to oxygen-dependent pathological conditions (shock, hypoxia and ischemia, cerebrovascular accident, intoxication with alcohol and antipsychotic drugs (antipsychotics)).
Mexidol ® improves cerebral metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, and reduces platelet aggregation. It stabilizes the membrane structures of blood cells (red blood cells and platelets) during hemolysis. It has a lipid-lowering effect, reduces the level of total cholesterol and LDL. Reduces enzymatic toxemia and endogenous intoxication in acute pancreatitis.
The mechanism of action of Mexidol ® is due to its antihypoxant, antioxidant and membrane-protective action. It inhibits lipid peroxidation processes, increases the activity of superoxide dismutase, increases the lipid-protein ratio, reduces the viscosity of the membrane, and increases its fluidity.
Modulates the activity of membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, acetylcholinesterase), receptor complexes (benzodiazepine, GABA, acetylcholine), which enhances their ability to bind to ligands, helps preserve the structural and functional transport of biomes. Mexidol ® increases dopamine in the brain. It causes an increase in the compensatory activity of aerobic glycolysis and a decrease in the degree of inhibition of oxidative processes in the Krebs cycle under conditions of hypoxia, with an increase in the content of ATP, creatine phosphate and activation of the energy-synthesizing functions of mitochondria, stabilization of cell membranes.
Mexidol ® normalizes metabolic processes in the ischemic myocardium, reduces the necrosis zone, restores and improves electrical activity and myocardial contractility, as well as increases coronary blood flow in the ischemic zone, and reduces the effects of reperfusion syndrome in acute coronary insufficiency. Increases antianginal activity of nitro drugs.
Mexidol ® contributes to the preservation of ganglion cells of the retina and optic nerve fibers with progressive neuropathy, the causes of which are chronic ischemia and hypoxia. Improves the functional activity of the retina and optic nerve, increasing visual acuity.
Pharmacokinetics
Absorption
With the introduction of Mexidol ® in doses of 400-500 mg Cmax in plasma is 3.5-4.0 μg / ml and is achieved within 0.45-0.5 hours.
Distribution of
After i / m administration, the drug is determined in blood plasma for 4 hours. The average retention time of the drug in the body is 0.7-1.3 hours.
Excretion
It is excreted in the urine mainly in a glucuronoconjugated form and in insignificant amounts unchanged.
Indications
acute cerebrovascular accident
traumatic brain injury, consequences of traumatic brain injury
discirculatory encephalopathy
vegetative dystonia syndrome srdlkrp neurocystic neurotic syndrome the composition of the complex therapy
primary open-angle glaucoma of various stages, as part of
complex therapy, relief of withdrawal symptoms in alcoholism with a predominance of neurosis-like and autonomic-vascular disorders
acute intoxication with antipsychotic agents
acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis).
Contraindications
hypersensitivity to the drug
acute impairment of liver and kidney function.
Strictly controlled clinical trials of the safety of using Mexidol ® in children, during pregnancy and lactation have not been conducted.
Pregnancy and lactation
No rigorously controlled clinical studies have been conducted on the safety of Mexidol ® during pregnancy and lactation.
Composition
1 ml
ethylmethylhydroxypyridine succinate 50 mg
Excipients:
sodium metabisulfite – 1 mg,
water d / a – up to 1 ml.
Dosage and administration of
i / m or iv (in a jet or drip). With the infusion method of administration, the drug should be diluted in a 0.9% sodium chloride solution.
Jetno Mexidol ® is administered slowly for 5 to 7 minutes, drip at a rate of 40 to 60 drops per minute. The maximum daily dose should not exceed 1200 mg.
In case of acute cerebrovascular accident, Mexidol ® is used in the first 10-14 days – iv drip 200-500 mg 2-4 times a day, then IM 200-250 mg 2-3 times a day for 2 weeks.
In case of traumatic brain injury and the consequences of traumatic brain injury, Mexidol ® is used intravenously in a drip of 200 – 500 mg 2-4 times a day for 10 to 15 days.
In case of dyscirculatory encephalopathy in the decompensation phase, Mexidol ® should be given iv in a drop or drop dose of 200-500 mg 1-2 times a day for 14 days. Then i / m at 100 – 250 mg / day for the next 2 weeks.
For the course of prophylaxis of dyscirculatory encephalopathy, the drug is administered intramuscularly at a dose of 200 – 250 mg 2 times a day for 10 to 14 days.
In case of mild cognitive impairment in elderly patients and anxiety disorders, the drug is used IM in a daily dose of 100-300 mg / day. for 14 to 30 days.
In acute myocardial infarction as part of complex therapy, Mexidol ® is administered intravenously or intramuscularly for 14 days, against the background of traditional therapy for myocardial infarction, including nitrates, beta-blockers, angiotensin converting enzyme inhibitors (ACEs), thrombolytics, anticoagulant and anticoagulant agents symptomatic remedies according to indications.
In the first 5 days, to achieve the maximum effect, it is advisable to administer the drug intravenously, in the next 9 days Mexidol ® can be administered intramuscularly.
Intravenous administration of the drug is carried out by drop infusion, slowly (to avoid side effects) in a 0.9% sodium chloride solution or 5% dextrose (glucose) solution in a volume of 100 – 150 ml for 30 – 90 minutes. If necessary, slow jet administration of the drug is possible, lasting at least 5 minutes.
The introduction of the drug (intravenous or intramuscular) is carried out 3 times a day, every 8 hours. The daily therapeutic dose is 6 – 9 mg / kg body weight per day, a single dose is 2 – 3 mg / kg body weight. The maximum daily dose should not exceed 800 mg, a single – 250 mg.
With open-angle glaucoma of various stages, Mexidol ® is administered intramuscularly at 100-300 mg / day, 1-3 times a day for 14 days as part of the complex therapy.
With withdrawal alcohol syndrome, Mexidol ® is administered at a dose of 200 – 500 mg iv / drop or IM 2 – 3 times a day for 5 – 7 days.
In acute intoxication with antipsychotics, the drug is administered iv in a dose of 200-500 mg / day for 7-14 days.
In acute purulent-inflammatory processes of the abdominal cavity (acute necrotic pancreatitis, peritonitis), the drug is prescribed on the first day both in the preoperative and postoperative period. The doses administered depend on the form and severity of the disease, the prevalence of the process, and options for the clinical course. Discontinuation of the drug should be done gradually only after a steady positive clinical and laboratory effect.
In acute edematous (interstitial) pancreatitis, Mexidol ® is prescribed 200 500 mg 3 times a day, iv / drop (in 0.9% sodium chloride solution) and / m. Mild severity of necrotic pancreatitis – 100-200 mg 3 times a day in / drip (in 0.9% sodium chloride solution) and / m. The average severity is 200 mg 3 times a day, in / drip (in 0.9% sodium chloride solution). Severe course – in a pulse dosage of 800 mg on the first day, with a double regimen of administration, then 200 to 500 mg 2 times a day with a gradual decrease in the daily dose. Extremely severe course – at an initial dosage of 800 mg / day until persistent relief of manifestations of pancreatogenic shock, to stabilize the state of 300 – 500 mg 2 times a day in / drip (in 0.9% sodium chloride solution) with a gradual decrease in the daily dosage.
Side effects
From the digestive system: rarely – nausea, dry mouth.
Other: rarely – allergic reactions.
Drug Interaction
When used together, Mexidol ® enhances the anxiolytics of benzodiazepine derivatives, antiparkinsonian (levodopa) and anticonvulsant (carbamazepine) agents.
Mexidol ® reduces the toxic effects of ethyl alcohol.
Overdose
Symptoms: possible drowsiness.
Storage conditions
In a dry, dark place at a temperature of no higher than 25 ° C.
Keep out of the reach of children.
Expiration
2 years.
Do not use after the expiry date stated on the package.
Deystvuyuschee substances
tylmetylhydroksypyrydyna succinate
Pharmasoft, Russia
